TransMedics Group (TMDX) Earnings Analysis

TransMedics Group (TMDX) next reports earnings on 2026-07-30, consensus EPS 0.5 USD. Last quarter (2025-10-29) it beat with EPS 0.66 USD vs 0.37 USD est (+78.4%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 14.16.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TMDX next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.5 USD
Revenue estimate0.18B

TMDX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-10-290.66 USD0.37 USD+78.4%Beat
2025-02-270.19 USD0.22 USD-13.6%Miss
2024-10-280.12 USD0.29 USD-58.6%Miss
2024-07-310.35 USD0.21 USD+66.7%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

TMDX valuation and analyst view

Trailing P/E14.16
Trailing EPS5 USD
Price / book4.96
Dividend yield0.00%
Market cap2.46B
Analyst consensusBuy (9 buy / 3 hold / 0 sell)
Avg price target107 USD

Related research pages

Frequently asked questions

When is TransMedics Group (TMDX)'s next earnings date?

TransMedics Group is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.5 USD and revenue estimate of 0.18B.

Did TMDX beat earnings last quarter?

In its 2025-10-29 report, TMDX posted EPS of 0.66 USD versus a 0.37 USD estimate — a beat of 78.4%.

What is TMDX's earnings track record?

Over the last 4 reported quarters with consensus data, TMDX beat estimates 2 times (50%).

What is TMDX's current P/E ratio and EPS?

TMDX trades at a trailing P/E of 14.16 on trailing EPS of 5.000086231449223 USD.

What do analysts rate TMDX?

Analyst consensus is "Buy" across 12 ratings (0 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 107 USD.